<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085579</url>
  </required_header>
  <id_info>
    <org_study_id>04-027</org_study_id>
    <secondary_id>MSKCC-04027</secondary_id>
    <nct_id>NCT00085579</nct_id>
  </id_info>
  <brief_title>Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>A Phase II Study of Maintenance Biotherapy With Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients With Metastatic Melanoma With a Partial Response or Stable Disease After Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill&#xD;
      melanoma cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving interleukin-2 together with&#xD;
      sargramostim works in treating patients with stage III or stage IV melanoma that was&#xD;
      previously treated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the frequency of complete response in patients with stage III or IV melanoma&#xD;
           who have achieved either a partial response or stable disease after prior systemic&#xD;
           chemotherapy and are treated with maintenance biotherapy comprising interleukin-2 and&#xD;
           sargramostim (GM-CSF).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the effects of this regimen on lymphocyte subsets in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to response to prior systemic chemotherapy (stable&#xD;
      disease [SD] vs partial response [PR]).&#xD;
&#xD;
      Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14 and low-dose&#xD;
      interleukin-2 (IL-2) SC on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days&#xD;
      for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      also receive pulses of high-dose IL-2* IV continuously over 42 hours on days 1 and 2 of&#xD;
      courses 2, 3, 5, 6, 8, 10 and 12.&#xD;
&#xD;
      NOTE: *Low-dose IL-2 and GM-CSF are not administered on days 1 and 2 of high-dose IL-2&#xD;
      administration&#xD;
&#xD;
      Patients who continue to have SD or a PR after 12 courses of therapy may continue to receive&#xD;
      treatment with GM-CSF and low-dose IL-2 as described above and high-dose IL-2 on days 1 and 2&#xD;
      of every third course.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-58 patients (10-29 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
               -  No primary ocular melanoma&#xD;
&#xD;
          -  Stable disease (SD) or partial response (PR) after prior systemic chemotherapy&#xD;
             completed at least 4 weeks ago&#xD;
&#xD;
               -  Patients whose second post-chemotherapy evaluation (performed at least 4 weeks&#xD;
                  after the first evaluation that demonstrated SD or PR AND within 2 weeks before&#xD;
                  study entry) of disease demonstrates continued tumor shrinkage are not eligible&#xD;
&#xD;
               -  Patients whose second evaluation shows disease progression are eligible unless&#xD;
                  one of the following is true:&#xD;
&#xD;
                    -  Lactic dehydrogenase (LDH) ≥ 2 times upper limit of normal (ULN)&#xD;
&#xD;
                    -  LDH &gt; ULN AND is higher than the patient's highest value before systemic&#xD;
                       chemotherapy&#xD;
&#xD;
                    -  Patient has developed a new tumor measuring &gt; 1 cm in diameter&#xD;
&#xD;
                    -  Sum of the longest diameters of the existing tumor has increased &gt; 20%&#xD;
&#xD;
          -  Evaluable or measurable disease&#xD;
&#xD;
          -  Not potentially curable by surgery&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Solitary brain metastasis allowed if completely resected or completely ablated&#xD;
                  with radiosurgery more than 1 month before study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Patients ≥ 50 years of age OR those with one or more cardiac risk factors must&#xD;
             demonstrate one of the following:&#xD;
&#xD;
               -  Normal exercise stress test&#xD;
&#xD;
               -  Normal stress thallium test&#xD;
&#xD;
               -  Normal comparable cardiac ischemia evaluation&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active infection requiring treatment&#xD;
&#xD;
          -  No concurrent medical or psychiatric condition that would increase the potential&#xD;
             toxicity of study treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic biologic response modifier therapy&#xD;
&#xD;
          -  No concurrent antineoplastic vaccine therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent antineoplastic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroidal antiemetics&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent antineoplastic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Surgery within the past 4 weeks allowed provided there is no evidence of disease&#xD;
             progression&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior therapy for melanoma&#xD;
&#xD;
          -  No other concurrent antineoplastic experimental therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul B. Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jedd D. Wolchok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

